In addition to the prothrombotic effect, the vasoconstrictive effect of selective COX-2 inhibitor
should be considered in patients with cardiovascular disease.
A recent analysis, published in the journal Rheumatology, found that the use of COX-2 inhibitors
more than doubles the risk of venous thromboembolism (VTE)--the development of a blood clot in a deep vein that may then travels to the lung and form a pulmonary embolism.
Editor's Note: "We found 30-day mortality from stroke increased by around 20% if patients were taking a COX-2 inhibitor
before admission," said study co-author Christian Christiansen, PhD, of Aarhus University Hospital.
Similar finding is observed in this present study where significant numbers of prescriptions containing preferential COX-2 inhibitor
After the Vioxx recall, other painkillers were prescribed to fill the gap, such as celecoxib (Celebrex), another COX-2 inhibitor
, nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, aspirin or naproxen, and opioid drugs.
29 December 2011 - Japanese RaQualia Pharma Inc said yesterday it had signed a Letter of Intent (LoI) with the Chinese Academy of Sciences and Guangzhou Great Water Tech Co Ltd for the licensing and joint development of the COX-2 inhibitor
, RQ-00317076, in China.
In 2000, Celebrex (celecoxib), the leading COX-2 inhibitor
, had sales of approximately $2.
For this study, we were interested only in those recipients who were continuously taking either a COX-2 inhibitor
, an NSAID, or other pain relieves throughout the 2-year study period.
5) For moderate to severe pain and inflammation, a COX-2 inhibitor
was the first choice, unless there is significant risk of hypertension or kidney disorder.
However, COX-2 inhibitors
have been linked to a heightened risk of heart problems (SN: 10/30/04, p.
Doctors should change the way they prescribe pain relievers for patients with or at high risk for cardiovascular disease and use selective COX-2 inhibitor
painkillers such as celecoxib (Celebrex) only as a last resort, the American Heart Association (AHA) has recommended.
Green tea alone reduced tumor growth by 42%, and the Cox-2 inhibitor
celecoxib slowed it by 57% on its own, according to a study published in last week's issue of the journal Clinical Cancer Research.